Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-02 · accession 0001562180-22-001078 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-03 | 2022-01-31 | SNDX | Meyers Michael L. | SVP, Chief Medical Off | J - Other | $12.39 | +1,714 | 23.3K | +8% | +$21.2K |
| D | 2022-02-03 | 2022-02-02 | SNDX | Meyers Michael L. | SVP, Chief Medical Off | A - Grant | $15.79 | +17.4K | 17.4K | New | +$274.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-31 | J | A | 1,714 | $12.39 | 23,280 | D | — | — | |
| 2 | Derivative | Stock Options (Right to buy) | 2022-02-02 | A | A | 17,350 | $15.79 | 17,350 | D | $15.79 · — to 2032-02-02 | 17,350 Common Stock | (F2) 1/23rd of the shares subject to the option shall vest monthly over a two-year period. |